Avid Bioservices Inc (CDMO)

[north40000]

OT from another board but applicable here:

"Merck ONCS Partnership was reported by Merck & Co. Inc. itself (which is very primed, if you ask me): https://www.gurufocus.com/news/518583/merck-collaborates-with-oncosec-medical-to-unlock-untapped-market-for-keytruda-

"Under the agreement, OncoSec will sponsor and fund the study and Merck will provide KEYTRUDA". KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

$ONCS Anticipated Study Start Date:
October 15, 2017
https://www.clinicaltrials.gov/ct2/show/NCT03132675?term=NCT03132675.&rank=1 "

The above seems to be the model PPHM is using in conjunction with its 3 trials with NCCN members. Perhaps it is the model used with MSKCC as well---I for one simply do not know.

Are all models that small biotechs use to enter the oncology space with BP identical to above? Sometimes, we see the milestones and royalty payments that accompany PRs like the above, payable to small company.

Why is the process above simply not reversed---BP funds the trial, and little biotech furnishes its drug/biologic to the collaboration? Is the process wholly a factor of negotiating power?